

## **Pediatric CIRB Meeting Agenda**

**May 14, 2020**

---

---

### **I. Continuing Review**

**AALL1131**, A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations (Protocol Version Date 12/28/18)

---

---

### **II. Continuing Review**

**AAML1531**, Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome: A COG Groupwide Phase III Study (Protocol Version Date 07/29/19)

---

---

### **III. Continuing Review**

**ANBL17P1**, A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, dinutuximab) (NSC# 764038, IND# 4308) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma (Protocol Version Date 10/24/19)

---

---

### **IV. Continuing Review**

**ARST1431**, A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temozolomide (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) (Protocol Version Date 11/19/18)

---

---

### **V. Continuing Review**

**PBTC-049**, A Phase I study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma and CNS tumors harboring MET aberrations. (Protocol Version Date 02/27/20)

---

---

---

---

**VI. New Study - Initial Review**

**ANBL19P1**, A Pilot Study of Dinutuximab in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma (Protocol Version Date 04/09/20)

---

---

**VII. Potential Unanticipated Problem and Serious and/or Continuing Noncompliance**

**APEC1621SC**, NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice) Screening Protocol (Protocol Version Date 03/11/20)

---

---